33d6df2f-acc4-4c91-b924-4fb2f519e8ed
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- ANGIOGENESIS+0.300
- COMPLEMENT+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- OXIDATIVE_PHOSPHORYLATION-0.600
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.300
- FATTY_ACID_METABOLISM-0.300
- MTORC1_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- ADIPOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- GLYCOLYSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290911 | — | — | 0.902 |
| 2 | 0056507f-a296-4148-bc9f-a831249c7973 | — | — | 0.879 |
| 3 | SRR10842349 | — | — | 0.865 |
| 4 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.864 |
| 5 | MDT-AP-1128 | Med | Medulloblastoma | 0.846 |
| 6 | TCGA-56-8309-01A-11R-2296-07 | — | cohortSQ1 | 0.846 |
| 7 | X17a4d870.71ef.4580.91db.071219517f26 | — | cohortSQ1 | 0.844 |
| 8 | MDT-AP-0390 | Med | Medulloblastoma | 0.843 |
| 9 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.841 |
| 10 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |